• Few studies have assessed racial/ethnic and gender differences in diabetes-related complications, healthcare resource utilization (HRU) and costs in patients with type 2 diabetes mellitus (T2DM). Research on Medicare recipients in the U.S. suggest that racial/ethnic disparities exist in the risk of developing T2DM, in related morbidity and mortality, and in healthcare quality and access. 1 Furthermore, women are more likely to be diagnosed with T2DM, to experience associated emotional distress, to have a poorer quality of life, use more healthcare services, and have a shorter lifespan. 2 • This study evaluated the extent to which health plan members' race/ethnicity or gender were associated with T2DM complication severity, healthcare resource use (HRU), and healthcare costs in a cohort of Medicare health plan members.
Objective
• Few studies have assessed racial/ethnic and gender differences in diabetes-related complications, healthcare resource utilization (HRU) and costs in patients with type 2 diabetes mellitus (T2DM). Research on Medicare recipients in the U.S. suggest that racial/ethnic disparities exist in the risk of developing T2DM, in related morbidity and mortality, and in healthcare quality and access. 1 Furthermore, women are more likely to be diagnosed with T2DM, to experience associated emotional distress, to have a poorer quality of life, use more healthcare services, and have a shorter lifespan. 2 • This study evaluated the extent to which health plan members' race/ethnicity or gender were associated with T2DM complication severity, healthcare resource use (HRU), and healthcare costs in a cohort of Medicare health plan members.
Methods, Cont'd
• -Demographic and clinical characteristics were assessed using univariate descriptive statistics. -The associations of race/ethnicity or gender with severity of T2DM complications, HRU, and costs were evaluated with generalized linear regression models. -The regression models were adjusted for age, region, LIS eligibility, RxRisk-V, depression, hypoglycemic events, and number of unique antidiabetic drug classes.
Limitations
• The identification of race/ethnicity using the Medicare database may be insufficient, especially for coding the 'Other' subgroup.
• Claims data are susceptible to missing data, as well as lack of data on indirect cost data, and patient lifestyles and attitudes
• The analysis were cross-sectional; subject identification did not require a baseline period prior to the 24-month study period, which may have created imbalances in follow-up times post-diagnosis, thereby affecting the calculation of the outcome measures.
• Data were obtained from a single health insurance company, which may limit their generalizability to other health plans and Medicare populations.
Conclusions
• The results support previous work suggesting that Medicare recipients with T2DM and major depression are more likely to be female and to be Hispanic compared to other racial/ethnic groups. 5 The exact reasons for these patterns are unknown and warrant more research, given the greater healthcare costs and utilization associated with diagnoses of depression and T2DM.
• Consistent with previous work, the results indicated that Black and Hispanic patients were more likely to utilize ER and inpatient services as compared to nonHispanic Whites. In addition, being Black or Hispanic was associated with lower all-cause healthcare costs. 6 Enhanced access to primary care may increase the availability of preventive care and reduce future ER visits and inpatient stays among these patients. Health plans and healthcare professionals may need to address any T2DM-related management challenges with Hispanic and Black patients as early in treatment as possible by encouraging them to attend followup outpatient visits and to adhere to their medication and lifestyle regimens. This attention may increase the likelihood that these patients' progress would be followed more closely so as to prevent or delay the onset of complications, which can be costly. 
Methods
• Study Design and Data Source: This was a retrospective cohort study of the medical and pharmacy claims of 333,576 Humana Medicare Advantage Plan (MAPD) members enrolled from 2010 -2011. A cross-sectional design was used: thus, outcomes and predictors were assessed during the same time period.
*SD = Standard deviation ; **LIS = Low Income Subsidy; ***RxRisk-V= a prescription claims-based comorbidity index *DCSI = Diabetes Complications Severity Index; **SD = Standard deviation *All costs are reported in US dollars ; **CI= confidence interval
